

## Special Issue

# Immunological Studies in Human Aging

### Message from the Guest Editor

Dear Colleagues We are pleased to invite you to submit your work to *Vaccines* in this Special Issue on immunological studies in human aging. Increased longevity in humans is multifactorial but significantly originates from sustaining immunity from early life to the end of life. This Special Issue aims to highlight novel studies, state-of-the-art reviews, and meta-analyses in the field of immunology in human aging.

Responsiveness to vaccination, novel vaccination strategies, and the understanding of immunological processes in the context of human aging are topics of interest. New findings on the role of immune cell populations, soluble factors (cytokines, chemokines), and other soluble factors (extracellular vesicles) of the innate and adaptive immune system are welcomed. Contributions of technological advances (immunoassays, data analysis) in this field will also be considered. Submissions related to the response to vaccination in older adults in the context of infectious diseases but also cancer are highly encouraged. We look forward to receiving your contributions.

---

### Guest Editor

Dr. Anis Larbi

1. Medical and Scientific Affairs, Beckman Coulter Life Sciences, 93420 Villepinte, France
2. Faculty of Medicine, University of Sherbrooke, Sherbrooke, QC J1H 5N4, Canada

---

### Deadline for manuscript submissions

closed (30 June 2023)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/si/151410](https://mdpi.com/si/151410)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Infectious Diseases)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).